ECT/Succinylcholine: Biochemical, Serum and Cardiovascular Changes
Status
Conditions
Details and patient eligibility
About
This study will be conducted to determine the pharmacodynamics, cardiovascular and biochemical effects of succinylcholine when given during electroconvulsive therapy. (ECT). This is a single center, prospective, study in patients who will be receiving ECT as indicated and prescribed by their psychiatrist. The study will be performed twice on each patient, 48-72 hours apart during consecutively scheduled ECT procedures.
Full description
Patients will receive the anesthetic that is traditionally given which includes appropriate doses of succinylcholine. Serum potassium and creatinine phosphokinase (CK) levels will be determined pre and post anesthesia; serum and urine myoglobin will be determined post anesthesia. Vital signs data [i.e., heart rate (arrhythmias) and arterial blood pressure] will be compared pre and post anesthesia. In addition patients will be asked about the presence of muscle pain (myalgia) 1 hour before discharge from the recovery room and the following day post ECT.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- A male or non-pregnant female aged 18 years and older
- American Society of Anesthesiologists physical status 1, 2, 3
- Scheduled to undergo electroconvulsive therapy under general anesthesia
- Have given written informed consent
Exclusion criteria
- Pregnant or nursing
- Any patient in the study investigators opinion who may not be suitable for research.
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal